So now 2 countries, Germany and Spain have rejected reimbursement for the greatest drug on earth or at least that's what many thought.
It looks like the EU is not going to be the savior for Amarin like many of us were hoping for. Since the US market has been plundered by the generics it seems the one drug enterprise will continue to languish.
I'm betting that not a single BP is interested in Amarin. I can't imagine that Denner has any rabbits in the hat in that regard. Many of us held through what was in fact the high water mark for the stock. Denner like many of us has been hosed as well. But unlike us he won't suffer the personal loss. Right now a break even pps would look very good. Not looking for gains any more on this one.
Market Data 
Markets 
AI
